Have your own idea? Try our Stock Screener
Hong Kong (HSI) Pharma Industry Analysis
UpdatedMar 22, 2026
DataAggregated Company Financials
Companies43
- 7D-0.7%
- 3M-9.3%
- 1Y38.6%
- YTD-6.4%
The Pharma industry has been flat over the last week, but Xuanzhu Biopharmaceutical has lost 14%. The past year has been better, since the industry has gained 39% in that time. Earnings are forecast to grow by 16% annually.
Industry Valuation and Performance
Has the Hong Kong Pharma Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sun, 22 Mar 2026 | HK$728.7b | HK$499.1b | HK$30.1b | 11.8x | 24.2x | 1.5x |
| Tue, 17 Feb 2026 | HK$825.2b | HK$497.3b | HK$30.5b | 13.8x | 27.1x | 1.7x |
| Thu, 15 Jan 2026 | HK$871.9b | HK$491.8b | HK$30.1b | 13.4x | 28.9x | 1.8x |
| Sat, 13 Dec 2025 | HK$835.2b | HK$485.7b | HK$29.8b | 13.5x | 28x | 1.7x |
| Mon, 10 Nov 2025 | HK$792.8b | HK$480.6b | HK$29.8b | 14x | 26.6x | 1.6x |
| Wed, 08 Oct 2025 | HK$815.8b | HK$479.7b | HK$30.6b | 13.6x | 26.6x | 1.7x |
| Fri, 05 Sep 2025 | HK$805.8b | HK$479.4b | HK$30.6b | 13.2x | 26.3x | 1.7x |
| Sun, 03 Aug 2025 | HK$745.2b | HK$473.3b | HK$29.0b | 11.7x | 25.7x | 1.6x |
| Tue, 01 Jul 2025 | HK$636.8b | HK$476.3b | HK$28.7b | 11x | 22.2x | 1.3x |
| Thu, 29 May 2025 | HK$565.9b | HK$477.5b | HK$28.8b | 10.8x | 19.6x | 1.2x |
| Sat, 26 Apr 2025 | HK$507.5b | HK$466.9b | HK$28.6b | 10.6x | 17.7x | 1.1x |
| Mon, 24 Mar 2025 | HK$470.9b | HK$466.4b | HK$31.8b | 9x | 14.8x | 1x |
| Wed, 19 Feb 2025 | HK$438.1b | HK$461.8b | HK$31.8b | 8.5x | 13.8x | 0.9x |
| Fri, 17 Jan 2025 | HK$398.7b | HK$459.3b | HK$31.7b | 8x | 12.6x | 0.9x |
| Sun, 15 Dec 2024 | HK$440.1b | HK$462.0b | HK$31.9b | 8.3x | 13.8x | 1x |
| Tue, 12 Nov 2024 | HK$442.2b | HK$466.5b | HK$32.4b | 8.4x | 13.7x | 0.9x |
| Thu, 10 Oct 2024 | HK$503.5b | HK$474.5b | HK$32.9b | 9x | 15.3x | 1.1x |
| Sat, 07 Sep 2024 | HK$438.9b | HK$474.5b | HK$32.9b | 7.9x | 13.3x | 0.9x |
| Mon, 05 Aug 2024 | HK$419.0b | HK$464.3b | HK$32.9b | 7.4x | 12.7x | 0.9x |
| Wed, 03 Jul 2024 | HK$435.9b | HK$461.4b | HK$33.7b | 8.3x | 12.9x | 0.9x |
| Fri, 31 May 2024 | HK$458.7b | HK$464.8b | HK$34.0b | 8.3x | 13.5x | 1x |
| Sun, 28 Apr 2024 | HK$459.0b | HK$463.7b | HK$33.8b | 7.5x | 13.6x | 1x |
| Tue, 26 Mar 2024 | HK$457.8b | HK$470.2b | HK$32.8b | 7.8x | 13.9x | 1x |
| Thu, 22 Feb 2024 | HK$439.6b | HK$471.0b | HK$33.6b | 7.8x | 13.1x | 0.9x |
| Sat, 20 Jan 2024 | HK$420.1b | HK$473.4b | HK$33.9b | 6.9x | 12.4x | 0.9x |
| Mon, 18 Dec 2023 | HK$489.7b | HK$472.9b | HK$33.8b | 8x | 14.5x | 1x |
| Wed, 15 Nov 2023 | HK$491.3b | HK$469.2b | HK$31.9b | 7x | 15.4x | 1x |
| Fri, 13 Oct 2023 | HK$445.8b | HK$469.4b | HK$31.6b | 7x | 14.1x | 0.9x |
| Sun, 10 Sep 2023 | HK$421.0b | HK$468.7b | HK$31.5b | 6.8x | 13.4x | 0.9x |
| Tue, 08 Aug 2023 | HK$444.3b | HK$446.2b | HK$27.8b | 8.7x | 16x | 1x |
| Thu, 06 Jul 2023 | HK$495.1b | HK$445.3b | HK$27.7b | 9.8x | 17.9x | 1.1x |
| Sat, 03 Jun 2023 | HK$511.8b | HK$449.8b | HK$28.0b | 8.5x | 18.3x | 1.1x |
| Mon, 01 May 2023 | HK$570.3b | HK$453.4b | HK$28.5b | 8.9x | 20x | 1.3x |
| Wed, 29 Mar 2023 | HK$544.1b | HK$443.6b | HK$33.8b | 8.9x | 16.1x | 1.2x |
Price to Earnings Ratio
16.1x
Current Industry PE
- Investors are optimistic on the Hong Kong Pharmaceuticals industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 24.0x which is higher than its 3-year average PE of 17.8x.
- The 3-year average PS ratio of 1.2x is lower than the industry's current PS ratio of 1.5x.
Past Earnings Growth
- The earnings for companies in the Pharmaceuticals industry have declined 3.6% per year over the last three years.
- Meanwhile revenues for these companies have grown 4.1% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Trends
Which industries have driven the changes within the Hong Kong Healthcare industry?
| HK Market | -0.88% | |
| Healthcare | -0.57% | |
| Pharma | -0.74% | |
| Pharma | -0.74% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 1093 CSPC Pharmaceutical Group | HK$8.80 | 2.4% +HK$2.4b | 81.4% | PE21.8x | |
| 867 China Medical System Holdings | HK$13.49 | 6.1% +HK$1.9b | 76.3% | PE19.3x | |
| 2630 Vigonvita Life Sciences | HK$126.00 | 12.9% +HK$960.2m | n/a | PS624.2x | |
| 1177 Sino Biopharmaceutical | HK$5.98 | 0.5% +HK$536.3m | 66.1% | PE24.1x | |
| 2652 CF PharmTech | HK$24.12 | 4.9% +HK$460.9m | n/a | PE314.4x |